Clinical Trial

CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase 2, prospective cohort clinical trial evaluating the utilization of CMV T Cell Immunity Panel (CMV-TCIP) assay to guide the duration of primary CMV prophylaxis in CMV-seropositive recipients of allogeneic stem cell transplant or recipients receiving a stem cell graft from a CMV serology positive donor.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-06-05; most recent amendment 2026-07-17.
Status change: Not Yet Recruiting → Recruiting 2024-07-02
Trial Details
NCT Number NCT06453460
Lead Sponsor University of California, Irvine
Collaborators: Eurofins Viracor
Conditions CMV, Allogeneic Stem Cell Transplantation
Enrollment 50 participants
Start Date 2024-06-27
Primary Completion 2028-06 (estimated)
Study Completion 2029-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-21